Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole in Breast Cancer Brain Metastases and Primary Gliomas
NCT03796273Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ketoconazole in breast cancer with brain metastasis (BCBM) and glioma (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: tGLI1 activation signature 8. Started Mar 2019; status: terminated.
02
Drugs
ketoconazole
03
Conditions
breast cancer with brain metastasis (BCBM)glioma
Beyond the preview
Go deeper on NCT03796273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796273.